Committed to the development
of innovative single domain antibody drugs
Novamab is located in the Shanghai International Medical Park (Pudong New District). It is an innovative biopharmaceutical company in the clinical stage, dedicated to developing VHH antibody drugs targeting the multi-billion-dollar markets of respiratory diseases and inflammatory disorders. Our mission is to develop life-changing therapies for patients through the research and development of innovative nanobodies (VHHs), while also enhancing drug efficacy and usability.
The company utilizes the advanced NanoVibe™ VHH platform to fully leverage the advantages of nanobodies, creating highly differentiated antibody drug platforms, including the inhaled antibody platform (Aerobody), the oral antibody platform (Orabody), and the dual/multi-antibody platform (Pluribody). Our product pipeline includes the FIC Phase II clinical inhaled IL-4R nanobody, the Phase I clinical inhaled TSLP nanobody, and multiple TL1A dual/multi-antibodies and oral pipelines, targeting indications such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).
The company has attracted the attention and support of several well-known investment institutions and funds, including Zhang Ke LINGYI, Qiming Venture Partners, and Shengdi Investment, among others. We currently have approximately 60 full-time employees so far.
The company concept can be started from the company name. The word nova in Novamab comes from Latin, meaning new, meaning "new". Mab is the abbreviation of monoclonal antibody, so Novamab means new antibody, while the development of VHH antibody has only been more than 20 years, and it is also a new antibody in the field of antibody research and development, so the two correspond to each other.
The "Y" shape in the company's icon represents the structural shape of the VHH antibody that lacks the light chain, and echoes with the VHH antibody again; In addition, the circular part of the icon is similar to a shield, indicating our desire and determination to defend human health, while the stars symbolize our good expectations for VHH antibody and ourselves. We hope that camel (camel and Luo) antibody can become a new star in the field of antibody medicine and start human future health.
Dr. Yakun Wan, founder and CEO of Novamab, has 17 years of VHH antibody research experience and is a leading figure in the field. He previously worked at the Shanghai Institute of Pharmaceutical Research, Chinese Academy of Sciences, and Southeast University. Dr. Wan also conducted postdoctoral research at the University of Texas at Austin, Baylor College of Medicine, and the American Institute of Systems Biology.
Dr. Wan has been honored with several awards, such as the "Hundred Talents Plan" by Shanghai Institute of Medicine, the Six Talent Peak Plans by Jiangsu Province, the "High-level Creative Talents Plan" by the Ministry of Education, and the "New Century Excellent Talents" award. He was also acknowledged as an "Outstanding Innovation and Entrepreneurship Talent" in 2021 and a "Pudong New Area Pearl Talent Leader" in 2024. Under his guidance, Novamab was recognized as one of China's top 50 innovative pharmaceutical enterprises in 2020 and a top 100 innovative seed enterprise in 2022.
Dr. Wan has authored over 70 scientific papers, with over 50 as first or corresponding author in SCI-indexed journals. He holds over 110 invention patents, 45 of which are authorized, and has led projects funded by the Shanghai Science and Technology Innovation Fund and the National Natural Science Foundation, among others.
Dr. Wan founded China's first VHH antibody R&D team in drug development, partnering with top pharmaceutical firms to progress several products to clinical phases. Novamab, with a complete R&D, pilot testing, and GMP production system, is uniquely positioned to handle full-process VHH antibody development in China. The 500L Pichia pastoris GMP pilot production workshop fills a significant industry void. Dr. Wan's team created the world's first inhaled VHH antibody drugs, LQ036 and LQ043H, targeting IL-4R and TSLP, respectively. These drugs are intended for patients with moderate-to-severe asthma, providing rapid local effects and low toxicity.